RankingsPricing
  1. US-listed companies
  2. NEUROCRINE BIOSCIENCES INC
  3. Financials
  4. Capital expenditures

NEUROCRINE BIOSCIENCES INCNBIX

Market cap
$15.2B
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-38+34.98%
Dec 31, 2023-28+71.52%
Dec 31, 2022-16-29.49%
Dec 31, 2021-23+114.68%
Dec 31, 2020-11-26.09%
Dec 31, 2019-15-40.56%
Dec 31, 2018-25+257.52%
Dec 31, 2017-7+68.94%
Dec 31, 2016-4+112.41%
Dec 31, 2015-2+19.98%
Dec 31, 2014-2+195.78%
Dec 31, 2013-1-43.87%
Dec 31, 2012-1+29.47%
Dec 31, 2011-1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)